Redox Signaling
- 1st Edition, Volume 162 - July 30, 2024
- Imprint: Academic Press
- Editors: Danyelle Townsend, Paul B. Fisher, Ed Schmidt, Kenneth D. Tew
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 2 9 4 4 4 - 0
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 9 4 4 5 - 7
Advances in Cancer Research, Volume 162 highlights new advances in the field, with this new volume presenting interesting chapters written by an international board of author… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAdvances in Cancer Research, Volume 162 highlights new advances in the field, with this new volume presenting interesting chapters written by an international board of authors.
- Provides the authority and expertise of leading contributors from an international board of authors
- Presents the latest release in the ACR series
- Updated release includes the latest information on the Advances in Cancer Research
Basic, translational, and clinical pancreatic cancer researchers, pancreatic cancer oncologists, molecular biologists, and immunologists, postdoctoral fellows, residents and fellows, and PhD and MD/PhD graduate students pursuing basic and translational pancreatic cancer research
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Chapter One: Unresolved questions regarding cellular cysteine sources and their possible relationships to ferroptosis
- Abstract
- 1 Roles and critical requirement of cellular cysteine
- 2 Ferroptosis
- 3 Role of GPX4 in ferroptosis
- 4 FSP1 and other enzymes affecting ferroptosis in parallel with GPX4
- 5 Genetic and pharmacologic models that question the exact roles of cystine, Cys, xCT, GSH, or GSH synthesis in ferroptosis
- 6 Potential roles of the thioredoxin system in ferroptosis
- 7 Concluding remarks
- Acknowledgments
- References
- Chapter Two: Protein Tyrosine Phosphatase regulation by Reactive Oxygen Species
- Abstract
- 1 Introduction
- 2 The Protein Tyrosine Phosphatase (PTP) catalytic domain
- 3 A Cys-based catalytic mechanism and sensitivity to oxidation
- 4 Sources of Reactive Oxygen Species (ROS) in cellular signaling
- 5 Oxidation of PTPs I: Cellular mechanisms
- 6 Oxidation of PTPs II: Structural aspects
- 7 Conclusions
- Acknowledgments
- References
- Chapter Three: Mitochondrial metallopeptidase OMA1 in cancer
- Abstract
- 1 Introduction
- 2 OMA1 and its role in mitochondrial and cellular physiology
- 3 Redox regulation of OMA1
- 4 OMA1 and its regulation in cancers
- 5 Clinical implications
- 6 Challenges and future directions
- Acknowledgments
- References
- Chapter Four: Role of antioxidants in modulating anti-tumor T cell immune resposne
- Abstract
- 1 Introduction
- Acknowledgment
- References
- Chapter Five: Redox pathways in melanoma
- Abstract
- Abbreviations
- 1 Introduction
- 2 Melanin biosynthesis
- 3 MGST1 and melanoma
- 4 MGST1 in melanoma metastasis and treatment response
- 5 Additional redox targets in melanoma
- Acknowledgments
- References
- Chapter Six: Melanoma redox biology and the emergence of drug resistance
- Abstract
- Abbreviations
- 1 Biology of melanoma
- 2 Treatment of melanoma
- 3 Drug resistance in melanoma
- 4 Oxidative stress in melanoma
- 5 Antioxidants in melanoma
- 6 Oxidative stress and BRAF inhibitor resistance
- Acknowledgments
- References
- Edition: 1
- Volume: 162
- Published: July 30, 2024
- No. of pages (Hardback): 182
- No. of pages (eBook): 312
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780443294440
- eBook ISBN: 9780443294457
DT
Danyelle Townsend
Affiliations and expertise
Pharmaceutical and Biomedical Sciences, Medical University of South Carolina, USAPF
Paul B. Fisher
Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
Affiliations and expertise
Department of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Virginia, USAKT
Kenneth D. Tew
Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.
Affiliations and expertise
Professor and Chairman, Department of Cell and Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USARead Redox Signaling on ScienceDirect